These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 22125944)

  • 1. Current management and future perspectives of overactive bladder (OAB) pharmacotherapy.
    Dobrek Ł; Juszczak K; Wyczółkowski M; Thor PJ
    Acta Pol Pharm; 2011; 68(6):807-21. PubMed ID: 22125944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimuscarinics and overactive bladder: other mechanism of action.
    Yamaguchi O
    Neurourol Urodyn; 2010; 29(1):112-5. PubMed ID: 19693952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for treatment of urinary incontinence.
    Vij M; Robinson D; Cardozo L
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):299-308. PubMed ID: 20384545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacotherapy of overactive bladder.
    Athanasopoulos A
    Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fesoterodine: a new agent for treating overactive bladder.
    Ellsworth P; Berriman SJ; Brodsky M
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in the medical management of overactive bladder.
    Robinson D; Giarenis I; Cardozo L
    Maturitas; 2013 Nov; 76(3):225-9. PubMed ID: 23953245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients.
    Michel MC; Oelke M; Goepel M; Beck E; Burkart M
    Neurourol Urodyn; 2007; 26(2):190-5. PubMed ID: 17096320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
    Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
    Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder.
    Latini JM; Giannantoni A
    Expert Opin Pharmacother; 2011 May; 12(7):1017-27. PubMed ID: 21473706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity.
    Cerruto MA; Asimakopoulos AD; Artibani W; Del Popolo G; La Martina M; Carone R; Finazzi-Agrò E
    Urol Int; 2012; 89(1):1-8. PubMed ID: 22738896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirabegron for overactive bladder syndrome.
    Drug Ther Bull; 2013 Aug; 51(8):90-2. PubMed ID: 23949821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxybutynin gel for the treatment of overactive bladder.
    Gomelsky A; Dmochowski RR
    Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder.
    Wagg A; Verdejo C; Molander U
    Int J Clin Pract; 2010 Aug; 64(9):1279-86. PubMed ID: 20529135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
    Wein AJ; Khullar V; Wang JT; Guan Z
    BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.